Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020

CAMBRIDGE, England--(BUSINESS WIRE)--Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, has been featured as one of the Sunday Times 10 Tech Track Ones to Watch 2020.

The Sunday Times launched the Tech Track 100 list 20 years ago to recognise Britain’s fastest-growing private technology companies. The Tech Track 10 Ones to Watch showcases companies that do not yet meet the criteria of the main Tech Track 100 league table, but which have achieved strong sales growth, are forecasting strong sales growth, and have innovative technologies.

The Sunday Times Tech Track 100 supplement including the 10 Ones to Watch was published on Sunday 6^th September 2020, within the business section of the Sunday Times. The digital edition can be downloaded from: www.fasttrack.co.uk.

Earlier this week, Cycle announced a $25m debt financing from Deutsche Bank AG.

About Cycle Pharmaceuticals

Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering best-in-class drug treatments and services to the under-served rare disease patient community. We focus on rare metabolic and neurological genetic conditions. Cycle is headquartered in Cambridge, UK and has offices in Boston, Mass. (USA). For more information, please visit www.cyclepharma.com and follow us on Twitter, LinkedIn, Facebook and Instagram.

Contacts

Cycle Pharmaceuticals
Paula Bekinschtein
Head of Global Marketing
Email: marketing@cyclepharma.com
Tel.: +44-1223-354118

Industry:

Cycle Pharmaceuticals

Release Summary

Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020

Release Versions

English Spanish (Summary)German French Italian Dutch (Summary)

Hashtags

Contacts

Cycle Pharmaceuticals
Paula Bekinschtein
Head of Global Marketing
Email: marketing@cyclepharma.com
Tel.: +44-1223-354118

Social Media Profiles

Cycle Pharmaceuticals on Facebook

Cycle Pharmaceuticals on Instagram

Cycle Pharmaceuticals on LinkedIn

Cycle Pharmaceuticals on Twitter

More News From Cycle Pharmaceuticals

Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US

DETROIT--(BUSINESS WIRE)--Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in partnership with Handa Therapeutics, LLC, and will be exclusively available through specialty pharmacy Onco360® with a specialty distribution network from McKesson, Cencora, and Cardinal Health. PHYRAGO is a tyrosine kinase inhibitor indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), adu...

Cycle Pharmaceuticals Signs Exclusive U.S. Sales License for PHYRAGO™ (dasatinib) Tablets

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals (Cycle Pharma) has entered into an exclusive U.S. commercialization agreement with Handa Therapeutics, LLC (Handa), for PHYRAGO, an FDA approved drug for treating two types of leukemia, Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). PHYRAGO will be Cycle Pharma’s first oncology product (its ninth commercial product) and will see th...

Cycle Pharmaceuticals launches HARLIKU™ (nitisinone) Tablets, the first FDA-approved treatment for use in Alkaptonuria (AKU)

BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals announced the launch of HARLIKU, the first and only FDA-approved treatment for reducing urinary homogentisic acid (HGA) in adult patients with alkaptonuria (AKU).1 AKU, also known as Black Bone Disease, is an ultra-rare genetic metabolic disorder that affects approximately one in 1,000,000 people in the US.2 HARLIKU can reduce urinary HGA production by up to 97% through the inhibition of an upstream enzyme.1 Clinical data demonstrated that nitisino...

Back to Newsroom